

Section 708A(5)(e) Notification

Melbourne – 31 October 2019: Genetic Technologies Limited ACN 009 212 328 (ASX: GTG) ("the Company"), refers to the issue of 928,397,236 ordinary shares in the Company on 28 October 2019.

The Corporations Act 2001 (the Act) restricts the on-sale of securities issued without disclosure, unless the sale is exempt under Section 708 or 708A of the Act. By the Company giving this notice, sale of securities noted above will fall within the exemption in Section 708A (5) of the Act.

In accordance with section 708A (6) of the Act, the following information is provided:

- a) this notice is given within 5 business days after the day of the issue;
- b) the issue is without disclosure to investors under Part 6D.2 of the Act;
- c) this notice is given under section 708A(5)(e) of the Act;
- d) as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company and section 674 of the Act; and
- e) as at the date of this notice, there is no excluded information to be provided in accordance with section 708A(7) and (8) of the Act.

Justyn Stedwell
Company Secretary
On behalf of the Board of Directors
Genetic Technologies Limited

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company's lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.

Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit www.gtglabs.com